Effect of Sini San prescription on apoptosis and proliferation of hepatocellular carcinoma HepG2 cells

doi:10.12047/j.cjap.5839.2020.104

Abstract

Abstract: Objective: To investigate the effects of Sini San prescription(SNS) on the proliferation and apoptosis of HepG2 cells and its molecular mechanism. Methods: The morphological changes of hepatocellular carcinoma HepG2 cells treated by SNS were observed by inverted microscope. MTT assay was used to detect the inhibitory effect of SNS on cell proliferation. Fluorescence staining and flow cytometry were employed to analyze the effect of SNS on apoptosis of HepG2 cells. Rho123 (Rhodamine 123) staining method was performed to detect the changes of mitochondrial membrane potential, and Western blot was used to evaluate the expression of proteins related to apoptosis. Results: The number of hepatocellular carcinoma HepG2 cells were significantly decreased (P＜0.01) and cells showed typical apoptotic cell morphology after treated with serum contained SNS. The inhibition rate of HepG2 cells was increased with the increase of concentration of serum contained SNS. The number of cells in G1 phase was significantly increased, while G2 phase was decreased after treated with serum contained SNS(P＜0.05).The apoptosis rate and mitochondrial membrane potential of HepG2 cells were significantly increased and decreased after treated with serum contained SNS(P＜0.05). The expression levels of Bax, caspase-3,-9 and cyt-c were significantly increased, while the expression of bcl-2 was decreased in HepG2 cells treated with serum contained SNS(P＜0.05).Conclusion: Sini San prescription can inhibit the proliferation of HepG2 cells and induce apoptosis by mitochondrial pathway.

Key words: Sini San prescription, hepatocellular carcinoma, HepG2 cells, apoptosis

CLC Number:

R966

ZHAO Jia-rong, FENG Xue-song, LI Hong, WANG Guo-quan, ZHANG Yan-fang, SHI Hai-long, LI Yuan-yuan, CHAO Xu. Effect of Sini San prescription on apoptosis and proliferation of hepatocellular carcinoma HepG2 cells[J]. CJAP, 2020, 36(5): 489-493.

References

[1] Freddie B, Jacques F, Isabelle S, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancersin 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424.
[2] 张博, 叶丽红. 中医药治疗原发性肝癌的实验研究概况[J]. 江苏中医药, 2012, 8: 75-77.
[3] 李洋, 李胜联. 传统中药复方四逆散治疗肝病的研究进展[J]. 内蒙古医科大学学报, 2013, 35(1): 80-83.
[4] 王付, 尚立芝, 苗小玲, 等. 四逆散加味治疗肝纤维化的临床疗效观察[J]. 中医药通报, 2012, 11(1): 42-45.
[5] 柴智, 樊慧杰, 王永辉, 等. 四逆散对雷公藤多苷所致急性肝损伤的影响[J]. 世界中西医结合杂志, 2012, 7(2): 120-123.
[6] 王道春, 苏全武. 加味四逆散对实验性肝硬化大鼠防治作用的研究[J]. 中西医结合研究, 2011, 3(2): 76-79.
[7] 芦志雁, 李丽. 解酲四逆散治疗酒精性肝病的疗效观察[J]. 中国药物与临床, 2008, 8(2): 155-156.
[8] 陈雨, 赵映前, 廖云龙, 等. 复方四逆散治疗43例慢性活动性乙型肝炎的临床观察[J]. 陕西医学院学报, 1996, 8(1): 4-5.
[9] 余榕键, 林丽珠, 郑聪敏, 等. 四逆散合四君子汤化裁方改善肝癌氩氦冷冻术后肝功能损害临床疗效观察[J]. 辽宁中医药大学学报, 2017, 19(5): 81-84.
[10]方晓芬, 赵磊, 吕宇克. 周维顺应用四逆散加减治疗肝癌经验[J]. 浙江中西医结合杂志, 2010, 20(7): 414.
[11]陈明义. 加味四逆散治疗原发性肝癌的临床及实验研究[D]. 广州中医药大学, 2014.
[12]European association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[13]张海芳, 王林, 刘洁, 等. 珊瑚树Vibsane型二萜类化合物对人体HepG2 细胞增殖的影响及其机制. 中国应用生理学杂志, 2014, 30(4): 343-347.
[14]包芳芳. 中医药治疗恶性肿瘤的策略和体会[J]. 天津中医药, 2011, 28(4): 351-352.
[15]Wan C, Chen Y, Yin P, Han D, et al. Transport stress induces apoptosis in ratmyocardial tissue via activation of the mitogen-activated protein kinase signaling pathways[J]. Heart Vessels, 2016, 31: 212212-212221.
[16]Adams JM, Cory S. Life -or -death decisions by the Bcl-2protein family[J]. Trends Biochem Sci, 2001, 26(1): 61-66.
[17]Muzio M, Chinnaiyan AM, Kischkel FC.FLICE, a novel FADD-homologous ICE/CED-3-like protease,is recruited tothe CD95 (Fas/APO-1) death-inducing signaling complex[J]. Cell, 1996, 85(6): 817-827.
[18]蒋盼若, 柯瑞君, 朱明了, 等. Smac类似物Birinapant的抗肝癌作用及相关分子机制[J]. 中国应用生理学杂志, 2018, 34(6): 524-529.